Enhancing Non-Invasive CML Diagnosis: High-Sensitivity Biosensors for Liquid Biopsy using Microfluidic chips

The BCR-ABL1 genetic fusion is the driving force in patients with myeloproliferative disorders having Chronic Myeloid Leukemia (CML), a type of cancer. Traditionally, diagnosis has traditionally been made by various invasive procedures such as bone marrow biopsy, which is painful, risky, and requires well-equipped health facilities; thus it is less accessible in resource-limited settings. Liquid biopsies can make use of peripheral blood samples, so it is possible to dispense with painful biopsies. Besides, biosensors have been designed capable of detecting CML biomarkers at a sensitive and specific level in blood samples. High sensitivity biosensor-integrated microfluidic chip technology for liquid biopsy-based diagnosis of CML is discussed in this research study. This can involve the detection of biomarkers at very low sample requirements with high diagnostic accuracy by combining microfluidic chips with biosensors. It might have an application in rapid, non-invasive, and accurate diagnosis of CML. It propels cancer diagnostics beyond former dependency on traditional biopsy procedures. In this regard, it may alter the diagnostic procedures of patients with CML because it presents an option which is less invasive, thereby availing the prospects of early diagnosis to a wider population segment.